Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gene therapy
|
| gptkbp:CD19Targeting |
yes
|
| gptkbp:clinicalTrialPhase |
Phase 1
|
| gptkbp:clinicalTrials.govID |
gptkb:NCT05020678
|
| gptkbp:developedBy |
gptkb:Nkarta_Therapeutics
|
| gptkbp:firstClinicalTrial |
2021
|
| gptkbp:geneticModification |
engineered to express anti-CD19 CAR
|
| gptkbp:hasCompany |
gptkb:South_San_Francisco,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
NKX019
|
| gptkbp:indication |
relapsed/refractory B-cell lymphoma
relapsed/refractory leukemia |
| gptkbp:manufacturer |
off-the-shelf
|
| gptkbp:mechanismOfAction |
targets CD19 antigen
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:source |
healthy donor NK cells
|
| gptkbp:sourceCellType |
engineered NK cells
|
| gptkbp:sponsor |
gptkb:Nkarta_Therapeutics
|
| gptkbp:target |
B-cell malignancies
|
| gptkbp:treatment |
allogeneic natural killer (NK) cell therapy
|
| gptkbp:trial |
gptkb:United_States
|
| gptkbp:trialStatus |
recruiting (as of 2024)
|
| gptkbp:bfsParent |
gptkb:Nkarta_Therapeutics
|
| gptkbp:bfsLayer |
7
|